Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Baxter
Medtronic
Harvard Business School
Mallinckrodt

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR METFORMIN HYDROCHLORIDE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Metformin Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004992 Diabetes Prevention Program Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 3 1996-07-01 The Diabetes Prevention Program is a nationwide clinical study to answer the question: Can Type 2 diabetes (also called noninsulin-dependent or adult-onset diabetes) be prevented or delayed? The study has recruited volunteers, who are at high risk of developing diabetes, at twenty-five medical centers in the United States. It is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and other Institute and corporate sponsors. Researchers will evaluate the efficacy of a lifestyle intervention and a pharmacological intervention in preventing or delaying Type 2 diabetes in persons with impaired glucose tolerance (IGT). Each person in the study will be followed for 3 to 6 years.
NCT00004992 Diabetes Prevention Program Completed National Institute on Aging (NIA) Phase 3 1996-07-01 The Diabetes Prevention Program is a nationwide clinical study to answer the question: Can Type 2 diabetes (also called noninsulin-dependent or adult-onset diabetes) be prevented or delayed? The study has recruited volunteers, who are at high risk of developing diabetes, at twenty-five medical centers in the United States. It is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and other Institute and corporate sponsors. Researchers will evaluate the efficacy of a lifestyle intervention and a pharmacological intervention in preventing or delaying Type 2 diabetes in persons with impaired glucose tolerance (IGT). Each person in the study will be followed for 3 to 6 years.
NCT00004992 Diabetes Prevention Program Completed National Institute on Minority Health and Health Disparities (NIMHD) Phase 3 1996-07-01 The Diabetes Prevention Program is a nationwide clinical study to answer the question: Can Type 2 diabetes (also called noninsulin-dependent or adult-onset diabetes) be prevented or delayed? The study has recruited volunteers, who are at high risk of developing diabetes, at twenty-five medical centers in the United States. It is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and other Institute and corporate sponsors. Researchers will evaluate the efficacy of a lifestyle intervention and a pharmacological intervention in preventing or delaying Type 2 diabetes in persons with impaired glucose tolerance (IGT). Each person in the study will be followed for 3 to 6 years.
NCT00004992 Diabetes Prevention Program Completed Office of Research on Women's Health (ORWH) Phase 3 1996-07-01 The Diabetes Prevention Program is a nationwide clinical study to answer the question: Can Type 2 diabetes (also called noninsulin-dependent or adult-onset diabetes) be prevented or delayed? The study has recruited volunteers, who are at high risk of developing diabetes, at twenty-five medical centers in the United States. It is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and other Institute and corporate sponsors. Researchers will evaluate the efficacy of a lifestyle intervention and a pharmacological intervention in preventing or delaying Type 2 diabetes in persons with impaired glucose tolerance (IGT). Each person in the study will be followed for 3 to 6 years.
NCT00004992 Diabetes Prevention Program Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Phase 3 1996-07-01 The Diabetes Prevention Program is a nationwide clinical study to answer the question: Can Type 2 diabetes (also called noninsulin-dependent or adult-onset diabetes) be prevented or delayed? The study has recruited volunteers, who are at high risk of developing diabetes, at twenty-five medical centers in the United States. It is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and other Institute and corporate sponsors. Researchers will evaluate the efficacy of a lifestyle intervention and a pharmacological intervention in preventing or delaying Type 2 diabetes in persons with impaired glucose tolerance (IGT). Each person in the study will be followed for 3 to 6 years.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Metformin Hydrochloride

Condition Name

Condition Name for Metformin Hydrochloride
Intervention Trials
Diabetes Mellitus, Type 2 412
Type 2 Diabetes Mellitus 354
Type 2 Diabetes 214
Diabetes 149
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Metformin Hydrochloride
Intervention Trials
Diabetes Mellitus 1139
Diabetes Mellitus, Type 2 1090
Polycystic Ovary Syndrome 134
Syndrome 113
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Metformin Hydrochloride

Trials by Country

Trials by Country for Metformin Hydrochloride
Location Trials
Canada 611
Japan 87
Slovakia 77
Czech Republic 77
Netherlands 74
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Metformin Hydrochloride
Location Trials
Texas 380
California 374
Florida 320
Ohio 252
North Carolina 242
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Metformin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Metformin Hydrochloride
Clinical Trial Phase Trials
Phase 4 513
Phase 3 528
Phase 2/Phase 3 48
[disabled in preview] 422
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Metformin Hydrochloride
Clinical Trial Phase Trials
Completed 1158
Recruiting 383
Not yet recruiting 204
[disabled in preview] 223
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Metformin Hydrochloride

Sponsor Name

Sponsor Name for Metformin Hydrochloride
Sponsor Trials
AstraZeneca 146
Novo Nordisk A/S 127
Merck Sharp & Dohme Corp. 110
[disabled in preview] 186
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Metformin Hydrochloride
Sponsor Trials
Other 1566
Industry 1350
NIH 121
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Dow
Moodys
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.